Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment

Advances in Cancer Research

Volumn 128, Issue , 2015, Pages 263-307

  Peske, J David ^a   Woods, Amber B ^a   Engelhard, Victor H ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Checkpoint blockade inhibitor; Chemokines; High endothelial venules; Integrins; Selectins; T cell trafficking; Tertiary lymphoid structures; Tumor associated vasculature; Tumor infiltrating lymphocytes

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; PADGEM PROTEIN; VASCULAR CELL ADHESION MOLECULE 1; LIGAND;

ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER PROGNOSIS; CD8+ T LYMPHOCYTE; CELL MIGRATION; COLORECTAL CANCER; DENDRITIC CELL; ENDOTHELIUM CELL; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; IMMUNOCOMPETENT CELL; KIDNEY CARCINOMA; LIVER METASTASIS; LYMPH NODE; LYMPHOCYTIC INFILTRATION; MELANOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANGIOGENESIS; BIOMECHANICS; CANCER IMMUNOTHERAPY; CANCER PATIENT; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; GENE EXPRESSION; LYMPHOCYTE MIGRATION; LYMPHOID ORGAN; TREATMENT RESPONSE; VASCULAR ENDOTHELIUM; VENULE; ANIMAL; IMMUNOLOGY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); VASCULARIZATION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MICROENVIRONMENT;

EID: 84952863049     PISSN: 0065230X     EISSN: 21625557     Source Type: Book Series    
DOI: 10.1016/bs.acr.2015.05.001     Document Type: Chapter

References (257)

1. Abdi R., Smith R.N., Makhlouf L., Najafian N., Luster A.D., Auchincloss H., et al. The role of CC chemokine receptor 5 (CCR5) in islet allograft rejection. Diabetes 2002, 51:2489-2495.
2. Afanasiev O.K., Nagase K., Simonson W., Vandeven N., Blom A., Koelle D.M., et al. Vascular E-selectin expression correlates with CD8 lymphocyte infiltration and improved outcome in Merkel cell carcinoma. The Journal of Investigative Dermatology 2013, 133:2065-2073. 10.1038/jid.2013.36.
3. Alimzhanov M.B., Kuprash D.V., Kosco-Vilbois M.H., Luz A., Turetskaya R.L., Tarakhovsky A., et al. Abnormal development of secondary lymphoid tissues in lymphotoxin β-deficient mice. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:9302-9307.
4. Aloisi F., Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nature Reviews. Immunology 2006, 6:205-217.
5. Alon R., Kassner P.D., Carr M.W., Finger E.B., Hemler M.E., Springer T.A. The integrin VLA-4 supports tethering and rolling in flow on VCAM-1. The Journal of Cell Biology 1995, 128:1243-1253.
6. Ando T., Jordan P., Wang Y., Itoh M., Joh T., Sasaki M., et al. MAdCAM-1 expression and regulation in murine colonic endothelial cells in vitro. Inflammatory Bowel Diseases 2005, 11:258-264.
7. Andrew D.P., Ruffing N., Kim C.H., Miao W., Heath H., Li Y., et al. C-C chemokine receptor 4 expression defines a major subset of circulating nonintestinal memory T cells of both Th1 and Th2 potential. Journal of Immunology 2001, 166:103-111.
8. Angell H., Galon J. From the immune contexture to the immunoscore: The role of prognostic and predictive immune markers in cancer. Current Opinion in Immunology 2013, 25:261-267. 10.1016/j.coi.2013.03.004.
9. Austrup F., Vestweber D., Borges E., Lohning M., Brauer R., Herz U., et al. P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflammed tissues. Nature 1997, 385:81-83.
10. Avram G., Sánchez-Sendra B., Martín J.M., Terrádez L., Ramos D., Monteagudo C. The density and type of MECA-79-positive high endothelial venules correlate with lymphocytic infiltration and tumour regression in primary cutaneous melanoma. Histopathology 2013, 63:852-861. 10.1111/his.12235.
11. Bailey S.R., Nelson M.H., Himes R.A., Li Z., Mehrotra S., Paulos C.M. Th17 cells in cancer: The ultimate identity crisis. Frontiers in Immunology 2014, 5:276. 10.3389/fimmu.2014.00276.
12. Balermpas P., Michel Y., Wagenblast J., Seitz O., Weiss C., Rödel F., et al. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. British Journal of Cancer 2014, 110:501-509. 10.1038/bjc.2013.640.
13. Barbera-Guillem E., Nelson M.B., Barr B., Nyhus J.K., May K.F., Feng L., et al. B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion. Cancer Immunology, Immunotherapy 2000, 48:541-549.
14. Baron J.L., Madri J.A., Ruddle N.H., Hashim G., Janeway C.A. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. The Journal of Experimental Medicine 1993, 177:57-68.
15. Barthel S.R., Gavino J.D., Descheny L., Dimitroff C.J. Targeting selectins and selectin ligands in inflammation and cancer. Expert Opinion on Therapeutic Targets 2007, 11:1473-1491. 10.1517/14728222.11.11.1473.
16. Beatty G.L., Haas A.R., Maus M.V., Torigian D.A., Soulen M.C., Plesa G., et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies. Cancer Immunology Research 2014, 2:112-120. 10.1158/2326-6066.CIR-13-0170.
17. Berg E.L., Yoshino T., Rott L.S., Robinson M.K., Warnock R.A., Kishimoto T.K., et al. The cutaneous lymphocyte antigen is a skin lymphocyte homing receptor for the vascular lectin endothelial cell-leukocyte adhesion molecule 1. The Journal of Experimental Medicine 1991, 174:1461-1466.
18. Berlin C., Bargatze R.F., Campbell J.J., von Andrian U.H., Szabo M.C., Hasslen S.R., et al. Alpha 4 integrins mediate lymphocyte attachment and rolling under physiologic flow. Cell 1995, 80:413-422.
19. Berlin C., Berg E.L., Briskin M.J., Andrew D.P., Kilshaw P.J., Holzmann B., et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 1993, 74:185-195.
20. Bernhard H., Neudorfer J., Gebhard K., Conrad H., Hermann C., Nährig J., et al. Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunology, Immunotherapy 2008, 57:271-280. 10.1007/s00262-007-0355-7.
21. Beverly B., Kang S.M., Lenardo M.J., Schwartz R.H. Reversal of in vitro T cell clonal anergy by IL-2 stimulation. International Immunology 1992, 4:661-671.
22. Blank C., Brown I., Kacha A.K., Markiewicz M.A., Gajewski T.F. ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo. Journal of Immunology 2005, 174:3416-3420.
23. Blank C., Brown I., Peterson A.C., Spiotto M., Iwai Y., Honjo T., et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Research 2004, 64:1140-1145.
24. Boissonnas A., Fetler L., Zeelenberg I.S., Hugues S., Amigorena S. In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. The Journal of Experimental Medicine 2007, 204:345-356. 10.1084/jem.20061890.
25. Borges E., Tietz W., Steegmaier M., Moll T., Hallmann R., Hamann A., et al. P-selectin glycoprotein ligand-1 (PSGL-1) on T helper 1 but not on T helper 2 cells binds to P-selectin and supports migration into inflamed skin. The Journal of Experimental Medicine 1997, 185:573-578.
26. Bourquin C., von der Borch P., Zoglmeier C., Anz D., Sandholzer N., Suhartha N., et al. Efficient eradication of subcutaneous but not of autochthonous gastric tumors by adoptive T cell transfer in an SV40 T antigen mouse model. Journal of Immunology 2010, 185:2580-2588. 10.4049/jimmunol.0903231.
27. Brinkman C.C., Rouhani S.J., Srinivasan N., Engelhard V.H. Peripheral tissue homing receptors enable T cell entry into lymph nodes and affect the anatomical distribution of memory cells. Journal of Immunology 2013, 191:2412-2425. 10.4049/jimmunol.1300651.
28. Brinkman C.C., Sheasley-O'Neill S.L., Ferguson A.R., Engelhard V.H. Activated CD8 T cells redistribute to antigen-free lymph nodes and exhibit effector and memory characteristics. Journal of Immunology 2008, 181:1814-1824.
29. Browning J.L., Allaire N., Ngam-Ek A., Notidis E., Hunt J., Perrin S., et al. Lymphotoxin-beta receptor signaling is required for the homeostatic control of HEV differentiation and function. Immunity 2005, 23:539-550. 10.1016/j.immuni.2005.10.002.
30. Buckanovich R.J., Facciabene A., Kim S., Benencia F., Sasaroli D., Balint K., et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nature Medicine 2008, 14:28-36. 10.1038/nm1699.
31. Bulliard Y., Jolicoeur R., Windman M., Rue S.M., Ettenberg S., Knee D.A., et al. Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. The Journal of Experimental Medicine 2013, 210:1685-1693. 10.1084/jem.20130573.
32. Butcher E.C. Leukocyte-endothelial cell recognition: Three (or more) steps to specificity and diversity. Cell 1991, 67:1033-1036. 10.1016/0092-8674(91)90279-8.
33. Calzascia T., Masson F., Di Berardino-Besson W., Contassot E., Wilmotte R., urrand-Lions M., et al. Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity 2005, 22:175-184.
34. Campbell D.J., Butcher E.C. Rapid acquisition of tissue-specific homing phenotypes by CD4(+) T cells activated in cutaneous or mucosal lymphoid tissues. The Journal of Experimental Medicine 2002, 195:135-141.
35. Campbell D.J., Debes G.F., Johnston B., Wilson E., Butcher E.C. Targeting T cell responses by selective chemokine receptor expression. Seminars in Immunology 2003, 15:277-286. S1044532303000642 [pii]. 10.1016/j.smim.2003.08.005.
36. Campbell J.J., Haraldsen G., Pan J., Rottman J., Qin S., Ponath P., et al. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 1999, 400:776-780.
37. Casares N., Pequignot M.O., Tesniere A., Ghiringhelli F., Roux S., Chaput N., et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. The Journal of Experimental Medicine 2005, 202:1691-1701. 10.1084/jem.20050915.
38. Cha E., Klinger M., Hou Y., Cummings C., Ribas A., Faham M., et al. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Science Translational Medicine 2014, 6:238ra70. 10.1126/scitranslmed.3008211.
39. Champiat S., Ferté C., Lebel-Binay S., Eggermont A., Soria J.C. Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy. OncoImmunology 2014, 3:e27817. 10.4161/onci.27817.
40. Chang C.-J., Tai K.-F., Roffler S., Hwang L.-H. The immunization site of cytokine-secreting tumor cell vaccines influences the trafficking of tumor-specific T lymphocytes and antitumor efficacy against regional tumors. Journal of Immunology 2004, 173:6025-6032. 10.4049/jimmunol.173.10.6025.
41. Chen J., Salas A., Springer T.A. Bistable regulation of integrin adhesiveness by a bipolar metal ion cluster. Nature Structural & Molecular Biology 2003, 10:995-1001. 10.1038/nsb1011.
42. Chen S.C., Vassileva G., Kinsley D., Holzmann S., Manfra D., Wiekowski M.T., et al. Ectopic expression of the murine chemokines CCL21a and CCL21b induces the formation of lymph node-like structures in pancreas, but not skin, of transgenic mice. Journal of Immunology 2002, 168:1001-1008.
43. Chong B.F., Murphy J.E., Kupper T.S., Fuhlbrigge R.C. E-selectin, thymus- and activation-regulated chemokine/CCL17, and intercellular adhesion molecule-1 are constitutively coexpressed in dermal microvessels: A foundation for a cutaneous immunosurveillance system. Journal of Immunology 2004, 172:1575-1581.
44. Chyou S., Ekland E.H., Carpenter A.C., Tzeng T.-C.J., Tian S., Michaud M., et al. Fibroblast-type reticular stromal cells regulate the lymph node vasculature. Journal of Immunology 2008, 181:3887-3896.
45. Cipponi A., Mercier M., Seremet T., Baurain J.-F., Théate I., van den Oord J., et al. Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Research 2012, 72:3997-4007. 10.1158/0008-5472.CAN-12-1377.
46. Clark W.H., Elder D.E., Guerry D., Braitman L.E., Trock B.J., Schultz D., et al. Model predicting survival in stage I melanoma based on tumor progression. Journal of the National Cancer Institute 1989, 81:1893-1904.
47. Clark R.A., Huang S.J., Murphy G.F., Mollet I.G., Hijnen D., Muthukuru M., et al. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. The Journal of Experimental Medicine 2008, 205:2221-2234. 10.1084/jem.20071190.
48. Coley W. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. The American Journal of the Medical Sciences 1893, 105:487-511.
49. Cook-Mills J.M., Marchese M.E., Abdala-Valencia H. Vascular cell adhesion molecule-1 expression and signaling during disease: Regulation by reactive oxygen species and antioxidants. Antioxidants & Redox Signaling 2011, 15:1607-1638. 10.1089/ars.2010.3522.
50. Coppola D., Nebozhyn M., Khalil F., Dai H., Yeatman T., Loboda A., et al. Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. The American Journal of Pathology 2011, 179:37-45. 10.1016/j.ajpath.2011.03.007.
51. Coursey T.G., Bohat R., Barbosa F.L., Pflugfelder S.C., de Paiva C.S. Desiccating stress-induced chemokine expression in the epithelium is dependent on upregulation of NKG2D/RAE-1 and release of IFN-γ in experimental dry eye. Journal of Immunology 2014, 193:5264-5272. 10.4049/jimmunol.1400016.
52. Coussens L.M., Tinkle C.L., Hanahan D., Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000, 103:481-490. 10.1016/S0092-8674(00)00139-2.
53. De Chaisemartin L., Goc J., Damotte D., Validire P., Magdeleinat P., Alifano M., et al. Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Research 2011, 71:6391-6399. 10.1158/0008-5472.CAN-11-0952.
54. 2+-dependent firm adhesion modalities for the α4β7-MAdCAM-1 interaction. Biochemistry 2001, 40:13972-13979. 10.1021/bi011582f.
55. De Palma M., Venneri M.A., Galli R., Sergi L.S., Politi L.S., Sampaolesi M., et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005, 8:211-226. 10.1016/j.ccr.2005.08.002.
56. De Togni P., Goellner J., Ruddle N.H., Streeter P.R., Fick A., Mariathasan S., et al. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 1994, 264:703-707.
57. Demaria S., Kawashima N., Yang A.M., Devitt M.L., Babb J.S., Allison J.P., et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clinical Cancer Research 2005, 11:728-734.
58. Demaria S., Ng B., Devitt M.L., Babb J.S., Kawashima N., Liebes L., et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. International Journal of Radiation Oncology, Biology, Physics 2004, 58:862-870. 10.1016/j.ijrobp.2003.09.012.
59. DeNardo D.G., Andreu P., Coussens L.M. Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Reviews 2010, 29:309-316. 10.1007/s10555-010-9223-6.
60. Deng L., Liang H., Xu M., Yang X., Burnette B., Arina A., et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type i interferon-dependent antitumor immunity in immunogenic tumors. Immunity 2014, 41:843-852. 10.1016/j.immuni.2014.10.019.
61. Denkert C., Loibl S., Noske A., Roller M., Müller B.M., Komor M., et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. Journal of Clinical Oncology 2010, 28:105-113. 10.1200/JCO.2009.23.7370.
62. Diederichsen A.C.P., Hjelmborg J.v.B., Christensen P.B., Zeuthen J., Fenger C. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunology, Immunotherapy 2003, 52:423-428. 10.1007/s00262-003-0388-5.
63. Dieu-Nosjean M.-C., Antoine M., Danel C., Heudes D., Wislez M., Poulot V., et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. Journal of Clinical Oncology 2008, 26:4410-4417. 10.1200/JCO.2007.15.0284.
64. Dieu-Nosjean M.-C., Goc J., Giraldo N.A., Sautès-Fridman C., Fridman W.H. Tertiary lymphoid structures in cancer and beyond. Trends in Immunology 2014, 35:571-580. 10.1016/j.it.2014.09.006.
65. DiLillo D.J., Yanaba K., Tedder T.F. B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: Therapeutic B cell depletion enhances B16 melanoma growth in mice. Journal of Immunology 2010, 184:4006-4016. 10.4049/jimmunol.0903009.
66. Dirkx A.E.M., oude Egbrink M.G., Kuijpers M.J., van der Niet S.T., Heijnen V.V., Bouma-ter Steege J.C., et al. Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Research 2003, 63:2322-2329.
67. Dong H., Strome S.E., Salomao D.R., Tamura H., Hirano F., Flies D.B., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nature Medicine 2002, 8:793-800.
68. Drayton D.L., Liao S., Mounzer R.H., Ruddle N.H. Lymphoid organ development: From ontogeny to neogenesis. Nature Immunology 2006, 7:344-353.
69. Dudda J.C., Lembo A., Bachtanian E., Huehn J., Siewert C., Hamann A., et al. Dendritic cells govern induction and reprogramming of polarized tissue-selective homing receptor patterns of T cells: Important roles for soluble factors and tissue microenvironments. European Journal of Immunology 2005, 35:1056-1065.
70. Economou J.S., Belldegrun A.S., Glaspy J., Toloza E.M., Figlin R., Hobbs J., et al. In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial. The Journal of Clinical Investigation 1996, 97:515-521. 10.1172/JCI118443.
71. Enarsson K., Johnsson E., Lindholm C., Lundgren A., Pan-Hammarström Q., Strömberg E., et al. Differential mechanisms for T lymphocyte recruitment in normal and neoplastic human gastric mucosa. Clinical Immunology 2006, 118:24-34. 10.1016/j.clim.2005.08.001.
72. Erdag G., Schaefer J.T., Smolkin M.E., Deacon D.H., Shea S.M., Dengel L.T., et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Research 2012, 72:1070-1080. 10.1158/0008-5472.CAN-11-3218.
73. Ericsson A., Kotarsky K., Svensson M., Sigvardsson M., Agace W. Functional characterization of the CCL25 promoter in small intestinal epithelial cells suggests a regulatory role for caudal-related homeobox (Cdx) transcription factors. Journal of Immunology 2006, 176:3642-3651. 10.4049/jimmunol.176.6.3642.
74. Ferguson A.R., Engelhard V.H. CD8 T cells activated in distinct lymphoid organs differentially express adhesion proteins and coexpress multiple chemokine receptors. Journal of Immunology 2010, 184:4079-4086. jimmunol.0901903 [pii]. 10.4049/jimmunol.0901903.
75. Fisher D.T., Chen Q., Skitzki J.J., Muhitch J.B., Zhou L., Appenheimer M.M., et al. IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. The Journal of Clinical Investigation 2011, 121:3846-3859. 10.1172/JCI44952.
76. Fisher B., Packard B.S., Read E.J., Carrasquillo J.A., Carter C.S., Topalian S.L., et al. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. Journal of Clinical Oncology 1989, 7:250-261.
77. Formenti S.C., Demaria S. Combining radiotherapy and cancer immunotherapy: A paradigm shift. Journal of the National Cancer Institute 2013, 105:256-265. 10.1093/jnci/djs629.
78. Fridman W.H., Pagès F., Sautès-Fridman C., Galon J. The immune contexture in human tumours: Impact on clinical outcome. Nature Reviews. Cancer 2012, 12:298-306. 10.1038/nrc3245.
79. Fuertes M.B., Kacha A.K., Kline J., Woo S.-R., Kranz D.M., Murphy K.M., et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells. The Journal of Experimental Medicine 2011, 208:2005-2016. 10.1084/jem.20101159.
80. Fuhlbrigge R.C., Kieffer J.D., Armerding D., Kupper T.S. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature 1997, 389:978-981.
81. Fuhlbrigge R.C., King S.L., Dimitroff C.J., Kupper T.S., Sackstein R. Direct real-time observation of E- and P-selectin-mediated rolling on cutaneous lymphocyte-associated antigen immobilized on Western blots. Journal of Immunology 2002, 168:5645-5651.
82. Fütterer A., Mink K., Luz A., Kosco-Vilbois M.H., Pfeffer K. The lymphotoxin β receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity 1998, 9:59-70. 10.1016/S1074-7613(00)80588-9.
83. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nature Reviews. Immunology 2012, 12:253-268. 10.1038/nri3175.
84. Gajewski T.F., Louahed J., Brichard V.G. Gene signature in melanoma associated with clinical activity. Cancer Journal 2010, 16:399-403. 10.1097/PPO.0b013e3181eacbd8.
85. Galon J., Angell H.K., Bedognetti D., Marincola F.M. The continuum of cancer immunosurveillance: Prognostic, predictive, and mechanistic signatures. Immunity 2013, 39:11-26. 10.1016/j.immuni.2013.07.008.
86. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pagès C., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964. 10.1126/science.1129139.
87. Ganss R., Hanahan D. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. Cancer Research 1998, 58:4673-4681.
88. Garbi N., Arnold B., Gordon S., Hämmerling G.J., Ganss R. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. Journal of Immunology 2004, 172:5861-5869.
89. Gatumu M.K., Skarstein K., Papandile A., Browning J.L., Fava R.A., Bolstad A. Blockade of lymphotoxin-beta receptor signaling reduces aspects of Sjögren syndrome in salivary glands of non-obese diabetic mice. Arthritis Research & Therapy 2009, 11:R24. 10.1186/ar2617.
90. Germain C., Gnjatic S., Tamzalit F., Knockaert S., Remark R., Goc J., et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. American Journal of Respiratory and Critical Care Medicine 2014, 189:832-844. 10.1164/rccm.201309-1611OC.
91. GeurtsvanKessel C.H., Willart M.A., Bergen I.M., van Rijt L.S., Muskens F., Elewaut D., et al. Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice. The Journal of Experimental Medicine 2009, 206:2339-2349. jem.20090410 [pii]. 10.1084/jem.20090410.
92. Girard J.-P., Moussion C., Förster R. HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes. Nature Reviews. Immunology 2012, 12:762-773. 10.1038/nri3298.
93. Goc J., Fridman W.-H., Sautès-Fridman C., Dieu-Nosjean M.-C. Characteristics of tertiary lymphoid structures in primary cancers. OncoImmunology 2013, 2:e26836. 10.4161/onci.26836.
94. Goelz S.E., Hession C., Goff D., Griffiths B., Tizard R., Newman B., et al. ELFT: A gene that directs the expression of an ELAM-1 ligand. Cell 1990, 63:1349-1356. 10.1016/0092-8674(90)90430-M.
95. Goelz S., Kumar R., Potvin B., Sundaram S., Brickelmaier M., Stanley P. Differential expression of an E-selectin ligand (SLex) by two Chinese hamster ovary cell lines transfected with the same alpha (1,3)-fucosyltransferase gene (ELFT). The Journal of Biological Chemistry 1994, 269:1033-1040.
96. -/- mice. The Journal of Experimental Medicine 2009, 206:233-248. 10.1084/jem.20080752.
97. Gregg R.K., Nichols L., Chen Y., Lu B., Engelhard V.H. Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice. Journal of Immunology 2010, 184:1909-1917. jimmunol.0902778 [pii]. 10.4049/jimmunol.0902778.
98. Griffith K.D., Read E.J., Carrasquillo J.A., Carter C.S., Yang J.C., Fisher B., et al. In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. Journal of the National Cancer Institute 1989, 81:1709-1717.
99. Halama N., Michel S., Kloor M., Zoernig I., Benner A., Spille A., et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Research 2011, 71:5670-5677. 10.1158/0008-5472.CAN-11-0268.
100. Halama N., Michel S., Kloor M., Zoernig I., Pommerencke T., von Knebel Doeberitz M., et al. The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. Cancer Immunity 2009, 9:1.
101. Hallahan D., Clark E.T., Kuchibhotla J., Gewertz B.L., Collins T. E-selectin gene induction by ionizing radiation is independent of cytokine induction. Biochemical and Biophysical Research Communications 1995, 217:784-795. 10.1006/bbrc.1995.2841.
102. Halle S., Dujardin H.C., Bakocevic N., Fleige H., Danzer H., Willenzon S., et al. Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells. The Journal of Experimental Medicine 2009, 206:2593-2601. jem.20091472 [pii]. 10.1084/jem.20091472.
103. Hamid O., Schmidt H., Nissan A., Ridolfi L., Aamdal S., Hansson J., et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. Journal of Translational Medicine 2011, 9:204. 10.1186/1479-5876-9-204.
104. Hammerschmidt S.I., Ahrendt M., Bode U., Wahl B., Kremmer E., Förster R., et al. Stromal mesenteric lymph node cells are essential for the generation of gut-homing T cells in vivo. The Journal of Experimental Medicine 2008, 205:2483-2490. 10.1084/jem.20080039.
105. Hamzah J., Jugold M., Kiessling F., Rigby P., Manzur M., Marti H.H., et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 2008, 453:410-414.
106. Hancock W.W., Lu B., Gao W., Csizmadia V., Faia K., King J.A., et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. The Journal of Experimental Medicine 2000, 192:1515-1520.
107. Hangalapura B.N., Oosterhoff D., Gupta T., de Groot J., Wijnands P.G.J.T.B., van Beusechem V.W., et al. Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine. Vaccine 2011, 29:2313-2321. 10.1016/j.vaccine.2011.01.022.
108. Hariri G., Zhang Y., Fu A., Han Z., Brechbiel M., Tantawy M.N., et al. Radiation-guided P-selectin antibody targeted to lung cancer. Annals of Biomedical Engineering 2008, 36:821-830. 10.1007/s10439-008-9444-9.
109. Harlin H., Meng Y., Peterson A.C., Zha Y., Tretiakova M., Slingluff C., et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Research 2009, 69:3077-3085. 10.1158/0008-5472.CAN-08-2281.
110. Henry R.A., Kendall P.L. CXCL13 blockade disrupts B lymphocyte organization in tertiary lymphoid structures without altering B cell receptor bias or preventing diabetes in nonobese diabetic mice. Journal of Immunology 2010, 185:1460-1465. 10.4049/jimmunol.0903710.
111. Herbst R.S., Soria J.-C., Kowanetz M., Fine G.D., Hamid O., Gordon M.S., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515:563-567. 10.1038/nature14011.
112. Hernot S., Klibanov A.L. Microbubbles in ultrasound-triggered drug and gene delivery. Advanced Drug Delivery Reviews 2008, 60:1153-1166. 10.1016/j.addr.2008.03.005.
113. Hindley J.P., Jones E., Smart K., Bridgeman H., Lauder S.N., Ondondo B., et al. T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion. Cancer Research 2012, 72:5473-5482. 10.1158/0008-5472.CAN-12-1912.
114. Hollenbaugh J.A., Dutton R.W. IFN-γ regulates donor CD8 T cell expansion, migration, and leads to apoptosis of cells of a solid tumor. Journal of Immunology 2006, 177:3004-3011. 10.4049/jimmunol.177.5.3004.
115. Homey B., Alenius H., Muller A., Soto H., Bowman E.P., Yuan W., et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nature Medicine 2002, 8:157-165.
116. Huang Y., Yuan J., Righi E., Kamoun W.S., Ancukiewicz M., Nezivar J., et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:17561-17566. 10.1073/pnas.1215397109.
117. Hubbard A.K., Rothlein R. Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades. Free Radical Biology & Medicine 2000, 28:1379-1386.
118. Ino Y., Yamazaki-Itoh R., Shimada K., Iwasaki M., Kosuge T., Kanai Y., et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. British Journal of Cancer 2013, 108:914-923. 10.1038/bjc.2013.32.
119. Irvine D.J., Stachowiak A.N., Hori Y. Lymphoid tissue engineering: Invoking lymphoid tissue neogenesis in immunotherapy and models of immunity. Seminars in Immunology 2008, 20:137-146. 10.1016/j.smim.2007.10.010.
120. Ji R.-R., Chasalow S.D., Wang L., Hamid O., Schmidt H., Cogswell J., et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunology, Immunotherapy 2012, 61:1019-1031. 10.1007/s00262-011-1172-6.
121. Johansson-Lindbom B., Svensson M., Wurbel M.A., Malissen B., Marquez G., Agace W. Selective generation of gut tropic T cells in gut-associated lymphoid tissue (GALT): Requirement for GALT dendritic cells and adjuvant. The Journal of Experimental Medicine 2003, 198:963-969.
122. Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:7556-7561.
123. Kaplanski G., Fabrigoule M., Boulay V., Dinarello C.A., Bongrand P., Kaplanski S., et al. Thrombin induces endothelial type II activation in vitro: IL-1 and TNF-alpha-independent IL-8 secretion and E-selectin expression. Journal of Immunology 1997, 158:5435-5441.
124. Kaplanski G., Marin V., Fabrigoule M., Boulay V., Benoliel A.-M., Bongrand P., et al. Thrombin-activated human endothelial cells support monocyte adhesion in vitro following expression of intercellular adhesion molecule-1 (ICAM-1; CD54) and vascular cell adhesion molecule-1 (VCAM-1; CD106). Blood 1998, 92:1259-1267.
125. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annual Review of Immunology 2008, 26:677-704.
126. Kenyon N.J., Liu R., O'Roark E.M., Huang W., Peng L., Lam K.S. An alpha4beta1 integrin antagonist decreases airway inflammation in ovalbumin-exposed mice. European Journal of Pharmacology 2009, 603:138-146. S0014-2999(08)01216-8 [pii]. 10.1016/j.ejphar.2008.11.063.
127. Kershaw M.H., Westwood J.A., Parker L.L., Wang G., Eshhar Z., Mavroukakis S.A., et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clinical Cancer Research 2006, 12:6106-6115. 10.1158/1078-0432.CCR-06-1183.
128. Kim H.-J., Kammertoens T., Janke M., Schmetzer O., Qin Z., Berek C., et al. Establishment of early lymphoid organ infrastructure in transplanted tumors mediated by local production of lymphotoxin α and in the combined absence of functional B and T cells. Journal of Immunology 2004, 172:4037-4047.
129. Kirk C.J., Hartigan-O'Connor D., Mule J.J. The dynamics of the T-cell antitumor response: Chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Research 2001, 61:8794-8802.
130. Kirk C.J., Hartigan-O'Connor D., Nickoloff B.J., Chamberlain J.S., Giedlin M., Aukerman L., et al. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine augmentation of dendritic cell-based immunotherapy. Cancer Research 2001, 61:2062-2070.
131. Knibbs R.N., Craig R.A., Natsuka S., Chang A., Cameron M., Lowe J.B., et al. The fucosyltransferase FucT-VII regulates E-selectin ligand synthesis in human T cells. The Journal of Cell Biology 1996, 133:911-920. 10.1083/jcb.133.4.911.
132. Koni P.A., Sacca R., Lawton P., Browning J.L., Ruddle N.H., Flavell R.A. Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin beta-deficient mice. Immunity 1997, 6:491-500.
133. Konkalmatt P.R., Deng D., Thomas S., Wu M.T., Logsdon C.D., French B.A., et al. Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Frontiers in Oncology 2013, 3:84. 10.3389/fonc.2013.00084.
134. Kunz M., Toksoy A., Goebeler M., Engelhardt E., Bröcker E., Gillitzer R. Strong expression of the lymphoattractant C-X-C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma. The Journal of Pathology 1999, 189:552-558.
135. Kupper T.S., Fuhlbrigge R.C. Immune surveillance in the skin: Mechanisms and clinical consequences. Nature Reviews. Immunology 2004, 4:211-222.
136. Kvistborg P., Philips D., Kelderman S., Hageman L., Ottensmeier C., Joseph-Pietras D., et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Science Translational Medicine 2014, 6:254ra128. 10.1126/scitranslmed.3008918.
137. Ladányi A., Sebestyén T., Mohos A., Liszkay G., Somlai B., Tóth E., et al. Ectopic lymphoid structures in primary cutaneous melanoma. Pathology Oncology Research 2014, 20:981-985. 10.1007/s12253-014-9784-8.
138. Lauder I., Aherne W. The significance of lymphocytic infiltration in neuroblastoma. British Journal of Cancer 1972, 26:321-330.
139. Lawrence M.B., Springer T.A. Leukocytes roll on a selectin at physiologic flow rates: Distinction from and prerequisite for adhesion through integrins. Cell 1991, 65:859-873.
140. Ley K., Laudanna C., Cybulsky M.I., Nourshargh S. Getting to the site of inflammation: The leukocyte adhesion cascade updated. Nature Reviews. Immunology 2007, 7:678-689.
141. Liao S., Ruddle N.H. Synchrony of high endothelial venules and lymphatic vessels revealed by immunization. Journal of Immunology 2006, 177:3369-3379.
142. Lin E.Y., Nguyen A.V., Russell R.G., Pollard J.W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. The Journal of Experimental Medicine 2001, 193:727-740. 10.1084/jem.193.6.727.
143. Liu H., Zhang T., Ye J., Li H., Huang J., Li X., et al. Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. Cancer Immunology, Immunotherapy 2012, 61:1849-1856. 10.1007/s00262-012-1231-7.
144. Lohr J., Ratliff T., Huppertz A., Ge Y., Dictus C., Ahmadi R., et al. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β. Clinical Cancer Research 2011, 17:4296-4308. 10.1158/1078-0432.CCR-10-2557.
145. Loi S., Sirtaine N., Piette F., Salgado R., Viale G., Eenoo F.V., et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy. Journal of Clinical Oncology 2013, 31:860-867. 10.1200/JCO.2011.41.0902.
146. Lugade A.A., Moran J.P., Gerber S.A., Rose R.C., Frelinger J.G., Lord E.M. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. Journal of Immunology 2005, 174:7516-7523.
147. Lurquin C., Lethé B., Plaen E.D., Corbière V., Théate I., van Baren N., et al. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. The Journal of Experimental Medicine 2005, 201:249-257. 10.1084/jem.20041378.
148. Luther S.A., Bidgol A., Hargreaves D.C., Schmidt A., Xu Y., Paniyadi J., et al. Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. Journal of Immunology 2002, 169:424-433.
149. Lutz E.R., Wu A.A., Bigelow E., Sharma R., Mo G., Soares K., et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunology Research 2014, 2:616-631. 10.1158/2326-6066.CIR-14-0027.
150. Maly P., Thall A., Petryniak B., Rogers C.E., Smith P.L., Marks R.M., et al. The alpha(1, 3)fucosyltransferase Fuc-TVII controls leukocyte trafficking through an essential role in L-, E-, and P-selectin ligand biosynthesis. Cell 1996, 86(4):643-653.
151. Margolin K.A. Interleukin-2 in the treatment of renal cancer. Seminars in Oncology 2000, 27:194-203.
152. Marincola F.M., Wang E., Herlyn M., Seliger B., Ferrone S. Tumors as elusive targets of T-cell-based active immunotherapy. Trends in Immunology 2003, 24:334-341. 10.1016/S1471-4906(03)00116-9.
153. Marinkovic T., Garin A., Yokota Y., Fu Y.X., Ruddle N.H., Furtado G.C., et al. Interaction of mature CD3+ CD4+ T cells with dendritic cells triggers the development of tertiary lymphoid structures in the thyroid. The Journal of Clinical Investigation 2006, 116:2622-2632.
154. Martinet L., Filleron T., Guellec S.L., Rochaix P., Garrido I., Girard J.-P. High endothelial venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotoxin β-producing dendritic cells in human breast cancer. Journal of Immunology 2013, 191:2001-2008. 10.4049/jimmunol.1300872.
155. Martinet L., Garrido I., Filleron T., Le Guellec S., Bellard E., Fournie J.-J., et al. Human solid tumors contain high endothelial venules: Association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Research 2011, 71:5678-5687. 10.1158/0008-5472.CAN-11-0431.
156. Martinet L., Le Guellec S., Filleron T., Lamant L., Meyer N., Rochaix P., et al. High endothelial venules (HEVs) in human melanoma lesions: Major gateways for tumor-infiltrating lymphocytes. OncoImmunology 2012, 1:829-839. 10.4161/onci.20492.
157. Masopust D., Schenkel J.M. The integration of T cell migration, differentiation and function. Nature Reviews. Immunology 2013, 13:309-320. 10.1038/nri3442.
158. Matsumoto M., Atarashi K., Umemoto E., Furukawa Y., Shigeta A., Miyasaka M., et al. CD43 functions as a ligand for E-selectin on activated T cells. Journal of Immunology 2005, 175:8042-8050.
159. Matsumoto M., Shigeta A., Furukawa Y., Tanaka T., Miyasaka M., Hirata T. CD43 collaborates with P-selectin glycoprotein ligand-1 to mediate E-selectin-dependent T cell migration into inflamed skin. Journal of Immunology 2007, 178:2499-2506. 178/4/2499 [pii].
160. Mebius R.E., Streeter P.R., Michie S., Butcher E.C., Weissman I.L. A developmental switch in lymphocyte homing receptor and endothelial vascular addressin expression regulates lymphocyte homing and permits CD4+ CD3- cells to colonize lymph nodes. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:11019-11024.
161. Messina J.L., Fenstermacher D.A., Eschrich S., Qu X., Berglund A.E., Lloyd M.C., et al. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: Potential for patient selection for immunotherapy?. Scientific Reports 2012, 2:765. 10.1038/srep00765.
162. Mionnet C., Sanos S.L., Mondor I., Jorquera A., Laugier J.-P., Germain R.N., et al. High endothelial venules as traffic control points maintaining lymphocyte population homeostasis in lymph nodes. Blood 2011, 118:6115-6122. 10.1182/blood-2011-07-367409.
163. Mlecnik B., Tosolini M., Charoentong P., Kirilovsky A., Bindea G., Berger A., et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 2010, 138:1429-1440. 10.1053/j.gastro.2009.10.057.
164. Mollà M., Gironella M., Miquel R., Tovar V., Engel P., Biete A., et al. Relative roles of ICAM-1 and VCAM-1 in the pathogenesis of experimental radiation-induced intestinal inflammation. International Journal of Radiation Oncology, Biology, Physics 2003, 57:264-273. 10.1016/S0360-3016(03)00523-6.
165. Mora J.R., Bono M.R., Manjunath N., Weninger W., Cavanagh L.L., Rosemblatt M., et al. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 2003, 424:88-93.
166. Mora J.R., Cheng G., Picarella D., Briskin M., Buchanan N., von Andrian U.H. Reciprocal and dynamic control of CD8 T cell homing by dendritic cells from skin- and gut-associated lymphoid tissues. The Journal of Experimental Medicine 2005, 201:303-316.
167. Mora J.R., von Andrian U.H. T-cell homing specificity and plasticity: New concepts and future challenges. Trends in Immunology 2006, 27:235-243.
168. Morales J., Homey B., Vicari A.P., Hudak S., Oldham E., Hedrick J., et al. CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:14470-14475.
169. Morris M., Platell C., Iacopetta B. Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy. Clinical Cancer Research 2008, 14:1413-1417. 10.1158/1078-0432.CCR-07-1994.
170. Motallebzadeh R., Rehakova S., Conlon T.M., Win T.S., Callaghan C.J., Goddard M., et al. Blocking lymphotoxin signaling abrogates the development of ectopic lymphoid tissue within cardiac allografts and inhibits effector antibody responses. The FASEB Journal 2012, 26:51-62. 10.1096/fj.11-186973.
171. Moussion C., Girard J.-P. Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules. Nature 2011, 479:542-546. 10.1038/nature10540.
172. Mullins D.W., Sheasley S.L., Ream R.M., Bullock T.N., Fu Y.X., Engelhard V.H. Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. The Journal of Experimental Medicine 2003, 198:1023-1034.
173. Mullins I.M., Slingluff C.L., Lee J.K., Garbee C.F., Shu J., Anderson S.G., et al. CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Research 2004, 64:7697-7701.
174. Nakano O., Sato M., Naito Y., Suzuki K., Orikasa S., Aizawa M., et al. Proliferative activity of intratumoral CD8+ T-lymphocytes as a prognostic factor in human renal cell carcinoma clinicopathologic demonstration of antitumor immunity. Cancer Research 2001, 61:5132-5136.
175. Nielsen J.S., Sahota R.A., Milne K., Kost S.E., Nesslinger N.J., Watson P.H., et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clinical Cancer Research 2012, 18:3281-3292. 10.1158/1078-0432.CCR-12-0234.
176. Novak L., Igoucheva O., Cho S., Alexeev V. Characterization of the CCL21-mediated melanoma-specific immune responses and in situ melanoma eradication. Molecular Cancer Therapeutics 2007, 6:1755-1764. 10.1158/1535-7163.MCT-06-0709.
177. Ogawa H., Binion D.G., Heidemann J., Theriot M., Fisher P.J., Johnson N.A., et al. Mechanisms of MAdCAM-1 gene expression in human intestinal microvascular endothelial cells. American Journal of Physiology. Cell Physiology 2005, 288:C272-C281. 10.1152/ajpcell.00406.2003.
178. Pagès F., Kirilovsky A., Mlecnik B., Asslaber M., Tosolini M., Bindea G., et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. Journal of Clinical Oncology 2009, 27:5944-5951. 10.1200/JCO.2008.19.6147.
179. Palma L., Di Lorenzo N., Guidetti B. Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases. Journal of Neurosurgery 1978, 49:854-861.
180. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews. Cancer 2012, 12:252-264. 10.1038/nrc3239.
181. Peng W., Liu C., Xu C., Lou Y., Chen J., Yang Y., et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Research 2012, 72:5209-5218. 10.1158/0008-5472.CAN-12-1187.
182. Peske J.D., Thompson E.D., Gemta L., Baylis R.A., Fu Y.-X., Engelhard V.H. Effector lymphocyte-induced lymph node-like vasculature enables naïve T-cell entry into tumors and enhanced anti-tumor immunity. Nature Communications 2015, 6:7114. 10.1038/ncomms8114.
183. Pockaj B.A., Sherry R.M., Wei J.P., Yannelli J.R., Carter C.S., Leitman S.F., et al. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 1994, 73:1731-1737.
184. Postow M.A., Callahan M.K., Barker C.A., Yamada Y., Yuan J., Kitano S., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. The New England Journal of Medicine 2012, 366:925-931. 10.1056/NEJMoa1112824.
185. Preston C.C., Maurer M.J., Oberg A.L., Visscher D.W., Kalli K.R., Hartmann L.C., et al. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. PLoS One 2013, 8:e80063. 10.1371/journal.pone.0080063.
186. Pylayeva-Gupta Y., Lee K.E., Hajdu C.H., Miller G., Bar-Sagi D. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 2012, 21:836-847. 10.1016/j.ccr.2012.04.024.
187. Quezada S.A., Peggs K.S., Simpson T.R., Shen Y., Littman D.R., Allison J.P. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. The Journal of Experimental Medicine 2008, 205:2125-2138. 10.1084/jem.20080099.
188. Rangel-Moreno J., Carragher D.M., de la Luz Garcia-Hernandez M., Hwang J.Y., Kusser K., Hartson L., et al. The development of inducible bronchus-associated lymphoid tissue depends on IL-17. Nature Immunology 2011, 12:639-646. 10.1038/ni.2053.
189. Remark R., Alifano M., Cremer I., Lupo A., Dieu-Nosjean M.-C., Riquet M., et al. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: Influence of tumor origin. Clinical Cancer Research 2013, 19:4079-4091. 10.1158/1078-0432.CCR-12-3847.
190. Restifo N.P., Dudley M.E., Rosenberg S.A. Adoptive immunotherapy for cancer: Harnessing the T cell response. Nature Reviews. Immunology 2012, 12:269-281. 10.1038/nri3191.
191. Rosen S.D. Ligands for L-selectin: Homing, inflammation, and beyond. Annual Review of Immunology 2004, 22:129-156.
192. Rosenberg S.A., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., Parkinson D.R., et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2 [see comments]. Journal of the American Medical Association 1994, 271:907-913.
193. Rott L.S., Briskin M.J., Andrew D.P., Berg E.L., Butcher E.C. A fundamental subdivision of circulating lymphocytes defined by adhesion to mucosal addressin cell adhesion molecule-1. Comparison with vascular cell adhesion molecule-1 and correlation with beta 7 integrins and memory differentiation. Journal of Immunology 1996, 156:3727-3736.
194. Sackstein R. The lymphocyte homing receptors: Gatekeepers of the multistep paradigm. Current Opinion in Hematology 2005, 12:444-450.
195. Sakai Y., Hoshino H., Kitazawa R., Kobayashi M. High endothelial venule-like vessels and lymphocyte recruitment in testicular seminoma. Andrology 2014, 2:282-289. 10.1111/j.2047-2927.2014.00192.x.
196. Salas A., Shimaoka M., Chen S., Carman C.V., Springer T. Transition from rolling to firm adhesion is regulated by the conformation of the I domain of the integrin lymphocyte function-associated antigen-1. The Journal of Biological Chemistry 2002, 277:50255-50262. 10.1074/jbc.M209822200.
197. Sandoval F., Terme M., Nizard M., Badoual C., Bureau M.-F., Freyburger L., et al. Mucosal imprinting of vaccine-induced CD8+ T cells is crucial to inhibit the growth of mucosal tumors. Science Translational Medicine 2013, 5:172ra20. 10.1126/scitranslmed.3004888.
198. Sato E., Olson S.H., Ahn J., Bundy B., Nishikawa H., Qian F., et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:18538-18543. 0509182102 [pii]. 10.1073/pnas.0509182102.
199. Schrama D., thor Straten P., Fischer W.H., McLellan A.D., Bröcker E.-B., Reisfeld R.A., et al. Targeting of lymphotoxin-α to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity 2001, 14:111-121. 10.1016/S1074-7613(01)00094-2.
200. Schrama D., Voigt H., Eggert A.O., Xiang R., Zhou H., Schumacher T.N.M., et al. Immunological tumor destruction in a murine melanoma model by targeted LTalpha independent of secondary lymphoid tissue. Cancer Immunology, Immunotherapy 2008, 57:85-95. 10.1007/s00262-007-0352-x.
201. Schwartzentruber D.J., Lawson D.H., Richards J.M., Conry R.M., Miller D.M., Treisman J., et al. gp100 Peptide vaccine and interleukin-2 in patients with advanced melanoma. The New England Journal of Medicine 2011, 364:2119-2127. 10.1056/NEJMoa1012863.
202. Seguin J., Nicolazzi C., Mignet N., Scherman D., Chabot G. Vascular density and endothelial cell expression of integrin alpha v beta 3 and E-selectin in murine tumours. Tumour Biology 2012, 33:1709-1717. 10.1007/s13277-012-0428-x.
203. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410:1107-1111.
204. Sharma S., Stolina M., Luo J., Strieter R.M., Burdick M., Zhu L.X., et al. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. Journal of Immunology 2000, 164:4558-4563.
205. Sheasley-O'Neill S.L., Brinkman C.C., Ferguson A.R., Dispenza M.C., Engelhard V.H. Dendritic cell immunization route determines integrin expression and lymphoid and nonlymphoid tissue distribution of CD8 T cells. Journal of Immunology 2007, 178:1512-1522.
206. Sherry B., Tekamp-Olson P., Gallegos C., Bauer D., Davatelis G., Wolpe S.D., et al. Resolution of the two components of macrophage inflammatory protein 1, and cloning and characterization of one of those components, macrophage inflammatory protein 1 beta. The Journal of Experimental Medicine 1988, 168:2251-2259. 10.1084/jem.168.6.2251.
207. Shields J.D., Kourtis I.C., Tomei A.A., Roberts J.M., Swartz M.A. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 2010, 328:749-752. 10.1126/science.1185837.
208. Shrimali R.K., Yu Z., Theoret M.R., Chinnasamy D., Restifo N.P., Rosenberg S.A. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Research 2010, 70:6171-6180. 10.1158/0008-5472.CAN-10-0153.
209. Sigmundsdottir H., Pan J., Debes G.F., Alt C., Habtezion A., Soler D., et al. DCs metabolize sunlight-induced vitamin D3 to "program" T cell attraction to the epidermal chemokine CCL27. Nature Immunology 2007, 8:285-293. ni1433 [pii]. 10.1038/ni1433.
210. Simpson T.R., Li F., Montalvo-Ortiz W., Sepulveda M.A., Bergerhoff K., Arce F., et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. The Journal of Experimental Medicine 2013, 210:1695-1710. 10.1084/jem.20130579.
211. Smyth M.J., Crowe N.Y., Godfrey D.I. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. International Immunology 2001, 13:459-463.
212. Smyth M.J., Thia K.Y., Street S.E., MacGregor D., Godfrey D.I., Trapani J.A. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. The Journal of Experimental Medicine 2000, 192:755-760.
213. Snyder A., Makarov V., Merghoub T., Yuan J., Zaretsky J.M., Desrichard A., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. The New England Journal of Medicine 2014, 371:2189-2199. 10.1056/NEJMoa1406498.
214. Spranger S., Bao R., Gajewski T. Melanoma-intrinsic β-catenin signaling prevents T cell infiltration and anti-tumor immunity. Journal for Immunotherapy of Cancer 2014, 2:O15. 10.1186/2051-1426-2-S3-O15.
215. Stark F.C., Gurnani K., Sad S., Krishnan L. Lack of functional selectin ligand interactions compromises long term tumor protection by CD8+ T cells. PLoS One 2012, 7:e32211. 10.1371/journal.pone.0032211.
216. Streeter P.R., Rouse B.T., Butcher E.C. Immunohistologic and functional characterization of a vascular addressin involved in lymphocyte homing into peripheral lymph nodes. The Journal of Cell Biology 1988, 107:1853-1862.
217. Sullivan R.J., Hoshida Y., Brunet J., Tahan S., Aldridge J., Kwabi C., et al. A single center experience with high-dose (HD) IL-2 treatment for patients with advanced melanoma and pilot investigation of a novel gene expression signature as a predictor of response. Journal of Clinical Oncology 2009, 27:15s.
218. Tensen C.P., Flier J., van der Raaj-Helmer E.M., Sampat-Sardjoepersad S., Van Der Schors R.C., Leurs R., et al. Human IP-9: A keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3). The Journal of Investigative Dermatology 1999, 112:716-722.
219. Thompson E.D., Enriquez H.L., Fu Y.-X., Engelhard V.H. Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. The Journal of Experimental Medicine 2010, 207:1791-1804. 10.1084/jem.20092454.
220. Thurner B., Haendle I., Roder C., Dieckmann D., Keikavoussi P., Jonuleit H., et al. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. The Journal of Experimental Medicine 1999, 190:1669-1678.
221. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine 2012, 366:2443-2454. 10.1056/NEJMoa1200690.
222. Tran D.Q., Ramsey H., Shevach E.M. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 2007, 110:2983-2990. 10.1182/blood-2007-06-094656.
223. Tsai S.-C., Lin S.-J., Lin C.-J., Chou Y.-C., Lin J.-H., Yeh T.-H., et al. Autocrine CCL3 and CCL4 induced by the oncoprotein LMP1 promote Epstein-Barr virus-triggered B cell proliferation. Journal of Virology 2013, 87:9041-9052. 10.1128/JVI.00541-13.
224. Tumeh P.C., Harview C.L., Yearley J.H., Shintaku I.P., Taylor E.J.M., Robert L., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515:568-571. 10.1038/nature13954.
225. Turk M.J., Guevara-Patiño J.A., Rizzuto G.A., Engelhorn M.E., Houghton A.N. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. The Journal of Experimental Medicine 2004, 200:771-782. 10.1084/jem.20041130.
226. Turnquist H.R., Lin X., Ashour A.E., Hollingsworth M.A., Singh R.K., Talmadge J.E., et al. CCL21 induces extensive intratumoral immune cell infiltration and specific anti-tumor cellular immunity. International Journal of Oncology 2007, 30:631-639.
227. Ulloa-Montoya F., Louahed J., Dizier B., Gruselle O., Spiessens B., Lehmann F.F., et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. Journal of Clinical Oncology 2013, 31:2388-2395. 10.1200/JCO.2012.44.3762.
228. Van de Pavert S.A., Mebius R.E. New insights into the development of lymphoid tissues. Nature Reviews. Immunology 2010, 10:664-674.
229. Van de Pavert S.A., Olivier B.J., Goverse G., Vondenhoff M.F., Greuter M., Beke P., et al. Chemokine CXCL13 is essential for lymph node initiation and is induced by retinoic acid and neuronal stimulation. Nature Immunology 2009, 10:1193-1199. 10.1038/ni.1789.
230. Vesely M., Kershaw M., Schreiber R., Smyth M. Natural innate and adaptive immunity to cancer. Annual Review of Immunology 2011, 29:235-271.
231. Victor C.T.-S., Rech A.J., Maity A., Rengan R., Pauken K.E., Stelekati E., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015, 520:373-377. Advance online publication. 10.1038/nature14292.
232. Von Andrian U.H., Mackay C.R. T-cell function and migration. Two sides of the same coin. The New England Journal of Medicine 2000, 343:1020-1034.
233. Vonderheide R.H., Bayne L.J. Inflammatory networks and immune surveillance of pancreatic carcinoma. Current Opinion in Immunology 2013, 25:200-205. 10.1016/j.coi.2013.01.006.
234. Wang L., Fan J., Thompson L.F., Zhang Y., Shin T., Curiel T.J., et al. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. The Journal of Clinical Investigation 2011, 121:2371-2382. 10.1172/JCI45559.
235. Wang J., Ioan-Facsinay A., van der Voort E.I.H., Huizinga T.W.J., Toes R.E.M. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. European Journal of Immunology 2007, 37:129-138. 10.1002/eji.200636435.
236. Wang X., Michie S.A., Xu B., Suzuki Y. Importance of IFN-gamma-mediated expression of endothelial VCAM-1 on recruitment of CD8+ T cells into the brain during chronic infection with Toxoplasma gondii. Journal of Interferon & Cytokine Research 2007, 27:329-338. 10.1089/jir.2006.0154.
237. Wang E., Miller L.D., Ohnmacht G.A., Mocellin S., Perez-Diez A., Petersen D., et al. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Research 2002, 62:3581-3586.
238. Wang T., Niu G., Kortylewski M., Burdelya L., Shain K., Zhang S., et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nature Medicine 2004, 10:48-54.
239. Webster B., Ekland E.H., Agle L.M., Chyou S., Ruggieri R., Lu T.T. Regulation of lymph node vascular growth by dendritic cells. The Journal of Experimental Medicine 2006, 203:1903-1913. 10.1084/jem.20052272.
240. Weis S.M., Cheresh D.A. Tumor angiogenesis: Molecular pathways and therapeutic targets. Nature Medicine 2011, 17:1359-1370. 10.1038/nm.2537.
241. Weishaupt C., Munoz K.N., Buzney E., Kupper T.S., Fuhlbrigge R.C. T-cell distribution and adhesion receptor expression in metastatic melanoma. Clinical Cancer Research 2007, 13:2549-2556. 10.1158/1078-0432.CCR-06-2450.
242. Weiss G.R., Grosh W.W., Chianese-Bullock K.A., Zhao Y., Liu H., Slingluff C.L., et al. Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma. Clinical Cancer Research 2011, 17:7440-7450. 10.1158/1078-0432.CCR-11-1650.
243. Weiss V.L., Lee T.H., Song H., Kouo T.S., Black C.M., Sgouros G., et al. Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells. PLoS One 2012, 7:e31962. 10.1371/journal.pone.0031962.
244. West N.R., Milne K., Truong P.T., Macpherson N., Nelson B.H., Watson P.H. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Research 2011, 13:R126. 10.1186/bcr3072.
245. Wiemann B., Starnes C.O. Coley's toxins, tumor necrosis factor and cancer research: A historical perspective. Pharmacology & Therapeutics 1994, 64:529-564.
246. Wilke C.M., Kryczek I., Wei S., Zhao E., Wu K., Wang G., et al. Th17 cells in cancer: Help or hindrance?. Carcinogenesis 2011, 32:643-649. 10.1093/carcin/bgr019.
247. Winograd R., Byrne K.T., Evans R.A., Odorizzi P.M., Meyer A.R.L., Bajor D.L., et al. Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma. Cancer Immunology Research 2015, 3:399-411. 10.1158/2326-6066.CIR-14-0215.
248. Woo S.-R., Fuertes M.B., Corrales L., Spranger S., Furdyna M.J., Leung M.Y.K., et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014, 41:830-842. 10.1016/j.immuni.2014.10.017.
249. Yang L., DeBusk L.M., Fukuda K., Fingleton B., Green-Jarvis B., Shyr Y., et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004, 6:409-421. 10.1016/j.ccr.2004.08.031.
250. Yang S.-C., Hillinger S., Riedl K., Zhang L., Zhu L., Huang M., et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clinical Cancer Research 2004, 10:2891-2901. 10.1158/1078-0432.CCR-03-0380.
251. Yao L., Setiadi H., Xia L., Laszik Z., Taylor F.B., McEver R.P. Divergent inducible expression of P-selectin and E-selectin in mice and primates. Blood 1999, 94:3820-3828.
252. Yasuda K., Nirei T., Sunami E., Nagawa H., Kitayama J. Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer. Radiation Oncology 2011, 6:1-6. 10.1186/1748-717X-6-49.
253. Yoong K.F., McNab G., Hübscher S.G., Adams D.H. Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma. Journal of Immunology 1998, 160:3978-3988.
254. Yu P., Lee Y., Liu W., Chin R.K., Wang J., Wang Y., et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nature Immunology 2004, 5:141-149.
255. Yu P., Lee Y., Liu W., Krausz T., Chong A., Schreiber H., et al. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. The Journal of Experimental Medicine 2005, 201:779-791. 10.1084/jem.20041684.
256. Zarbock A., Ley K., McEver R.P., Hidalgo A. Leukocyte ligands for endothelial selectins: Specialized glycoconjugates that mediate rolling and signaling under flow. Blood 2011, 118:6743-6751. 10.1182/blood-2011-07-343566.
257. Zitvogel L., Kepp O., Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nature Reviews. Clinical Oncology 2011, 8:151-160. 10.1038/nrclinonc.2010.223.